Literature DB >> 17381371

Underutilization of evidence-based therapies in heart failure: the pharmacist's role.

Jo Ellen Rodgers1, Wendy Gattis Stough.   

Abstract

Utilization of evidence-based therapy in the heart failure population includes implementation of heart failure treatment guidelines, interventions to improve prescribing, and inclusion of pharmacists on the multidisciplinary team. Use of treatment guidelines eases the challenge of selecting the appropriate drug and dosage; quality interventions by pharmacists can ensure optimal prescribing of therapy; and provision of care by a multidisciplinary team can improve outcomes in patients with heart failure. Evidence-based therapy, however, remains underutilized in the heart failure population. Barriers to utilization include misperceptions that various heart failure subpopulations do not need certain medical therapies, a fear of polypharmacy, inappropriate assumptions about adverse effects and contraindications, and cost. In fact, optimal prescribing of evidence-based therapy can actually reduce costs. Clearly documented processes and systems are needed to ensure that evidence-based therapy and education are available to every patient.

Entities:  

Mesh:

Year:  2007        PMID: 17381371     DOI: 10.1592/phco.27.4part2.18S

Source DB:  PubMed          Journal:  Pharmacotherapy        ISSN: 0277-0008            Impact factor:   4.705


  8 in total

1.  Implementing pharmacy practice research programs for the management of heart failure.

Authors:  Michael D Murray
Journal:  Pharm World Sci       Date:  2010-10

2.  Evaluation of health research: measuring costs and socioeconomic effects.

Authors:  Kerstin Roback; Koustuv Dalal; Per Carlsson
Journal:  Int J Prev Med       Date:  2011-10

Review 3.  Current perspectives on the role of the pharmacist in heart failure management.

Authors:  Judy Wm Cheng
Journal:  Integr Pharm Res Pract       Date:  2018-03-09

4.  Drug-Therapy Problems and Predictors among Hospitalized Heart-Failure Patients: A Prospective Observational Study.

Authors:  Teklehaimanot Fentie Wendie; Mulugeta Tarekegn Angamo
Journal:  Drug Healthc Patient Saf       Date:  2020-12-22

5.  Prescribing Data in General Practice Demonstration (PDGPD) project--a cluster randomised controlled trial of a quality improvement intervention to achieve better prescribing for chronic heart failure and hypertension.

Authors:  Margaret Williamson; Magnolia Cardona-Morrell; Jeffrey D Elliott; James F Reeve; Nigel P Stocks; Jon Emery; Judith M Mackson; Jane M Gunn
Journal:  BMC Health Serv Res       Date:  2012-08-23       Impact factor: 2.655

6.  Utilization of evidence-based treatment in elderly patients with chronic heart failure: using Korean Health Insurance claims database.

Authors:  Ju-Young Kim; Hwa-Jung Kim; Sun-Young Jung; Kwang-Il Kim; Hong Ji Song; Joong-Yub Lee; Jong-Mi Seong; Byung-Joo Park
Journal:  BMC Cardiovasc Disord       Date:  2012-07-31       Impact factor: 2.298

Review 7.  Treatment Considerations and the Role of the Clinical Pharmacist Throughout Transitions of Care for Patients With Acute Heart Failure.

Authors:  Elizabeth B McNeely
Journal:  J Pharm Pract       Date:  2016-04-28

Review 8.  A Review of the Role of the Pharmacist in Heart Failure Transition of Care.

Authors:  Sarah L Anderson; Joel C Marrs
Journal:  Adv Ther       Date:  2018-02-27       Impact factor: 3.845

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.